Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ15210MR)

This product GTTS-WQ15210MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Rheumatoid arthritis (RA) research.

Specifications
Product type	mRNA
Modified bases	Pseudo-UTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_001198622.2; NM_001145645.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	8741; 10673
UniProt ID	Q2QBA2; Q9Y275

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15210MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ2794MR	IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	AMG-282
GTTS-WQ214MR	IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	13C5.5
GTTS-WQ5637MR	IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	CDP870
GTTS-WQ7292MR	IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	FPA-008
GTTS-WQ8983MR	IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	ILV-094
GTTS-WQ1775MR	IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	ADCT-301(unconjugated)
GTTS-WQ7306MR	IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	FPA-008
GTTS-WQ6433MR	IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	CT-P22

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST